Phathom Pharmaceuticals shares drop after public offering announcement
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 18 2024
0mins
Should l Buy PHAT?
Source: MarketWatch
Phathom Pharmaceuticals Inc shares fell by 14.33% as the stock crossed below the 5-day SMA, reflecting investor concerns following the company's announcement of a public offering.
The decline is attributed to the company's recent announcement of a public offering to raise approximately $130 million, which may dilute existing shareholders' equity. This offering, priced at $16 per share, aims to fund research and development efforts, particularly for its innovative drug vonoprazan. Despite the anticipated increase in Q4 sales, the market reacted negatively to the potential dilution and uncertainty surrounding the offering's impact on the company's financial health.
This situation highlights the delicate balance between raising capital for growth and maintaining shareholder value. Investors will be closely monitoring the market's response to the offering and the company's ability to leverage the funds effectively for future growth.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PHAT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PHAT
Wall Street analysts forecast PHAT stock price to rise
6 Analyst Rating
5 Buy
1 Hold
0 Sell
Strong Buy
Current: 12.630
Low
16.00
Averages
25.40
High
29.00
Current: 12.630
Low
16.00
Averages
25.40
High
29.00
About PHAT
Phathom Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases. The Company’s product candidates include VOQUEZNA, VOQUEZNA TRIPLE PAK, and VOQUEZNA DUAL PAK. Its product candidate, VOQUEZNA, contains vonoprazan, an oral small molecule potassium-competitive acid blocker, or potassium-competitive acid blocker (PCAB). PCABs are a novel class of medicines that block acid secretion in the stomach. Vonoprazan has also demonstrated clinical benefits in the treatment of erosive gastroesophageal reflux disease (erosive GERD), and in combination with antibiotics for the treatment of Helicobacter pylori (H. pylori) infection. GERD and H. pylori infection are two of the most common acid-related GI diseases. GERD is a disease that develops when the reflux of acidic stomach contents causes troublesome symptoms and/or complications. H. pylori is a bacterial pathogen.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Barclays Upgrades Phathom to Overweight Amid Sales Recovery Prospects
- Rating Upgrade: Barclays upgraded Phathom Pharmaceuticals (PHAT) from equal weight to overweight, reflecting confidence in the anticipated sales recovery of its heartburn drug Voquezna, with significant growth expected in Q2.
- Price Target Adjustment: The bank raised its price target for Phathom from $16 to $18, indicating approximately 67% upside based on the March 26 close, showcasing a positive outlook on the company's future performance.
- Improving Sales Trends: Despite a ~36% year-to-date decline in Phathom's stock price, analysts noted positive sales trends in March, particularly with prescriptions peaking on March 13, surpassing levels seen in Q4 2025, indicating a rebound in market demand.
- Strategic Commercial Focus: Phathom's targeted approach towards gastrointestinal providers rather than a broader GI and primary care focus may serve as a tailwind for increased adoption of Voquezna, suggesting that this strategic positioning could enhance market penetration.
See More
PHATHOM PHARMACEUTICALS INC.: BARCLAYS INCREASES TARGET PRICE FROM $16 TO $18
- Analyst Update: Barclays has raised the price target for Phathom Pharmaceuticals from $16 to $18.
- Market Implications: This adjustment reflects a positive outlook on the company's performance and potential growth in the pharmaceutical sector.
See More
Surge in Options Trading Volume for Adobe and Phathom Pharmaceuticals
- Adobe Options Volume: Adobe Inc saw options trading volume of 58,412 contracts, equivalent to approximately 5.8 million shares, representing about 88.3% of its average daily trading volume of 6.6 million shares over the past month, indicating strong market interest in its future performance.
- High Put Option Activity: Notably, the $290 strike put option has seen 5,001 contracts traded today, representing around 500,100 shares of Adobe, reflecting investor expectations for potential price declines.
- Phathom Options Activity: Phathom Pharmaceuticals Inc recorded an options trading volume of 10,012 contracts, equivalent to approximately 1.0 million shares, which is about 86.9% of its average daily trading volume of 1.2 million shares over the past month, showcasing significant market interest.
- Call Option Trading: For Phathom, the $7.50 strike call option has also seen a trading volume of 5,001 contracts today, representing approximately 500,100 shares, indicating investor confidence in the company's future price appreciation.
See More
Emerging Trends in H. pylori Infection Market
- Market Size Growth: The H. pylori infection market is projected to reach $270 million by 2025, with the U.S. accounting for 85% of this market, indicating strong demand for new therapies and significant future market potential.
- Emerging Therapy Development: New therapies like Rifasutenizol from TenNor Therapeutics show over 90% eradication rates in clinical trials, potentially becoming the first innovative therapy for H. pylori, enhancing treatment efficacy and reducing resistance risks.
- Optimized Treatment Strategies: The incorporation of bismuth into triple therapy has increased eradication rates by 30-40%, reflecting effective strategies against antibiotic-resistant H. pylori and driving improvements in treatment standards.
- Adult-Pediatric Treatment Differences: Adult guidelines emphasize widespread eradication to lower gastric cancer risks, while pediatric recommendations require more cautious, targeted strategies, creating opportunities for personalized prevention and intervention programs.
See More
Phathom Pharmaceuticals Q4 2025 Earnings Call Highlights
- Strong Financial Performance: Phathom Pharmaceuticals reported Q4 2025 net revenues of $57.6 million, reflecting a 16% sequential growth, indicating significant improvements in sales and operational efficiency, with 2026 revenue guidance projected between $320 million and $345 million, showcasing robust market demand and growth potential.
- Capital Structure Optimization: The company successfully completed a $130 million equity offering and renegotiated debt terms, reducing the loan interest rate from 12% to 9.85%, which will significantly alleviate future financial burdens and enhance the company's financial flexibility and sustainability.
- Significant Prescription Growth: To date, total prescriptions for VOQUEZNA have exceeded 1.1 million, with Q4 alone reaching 273,000 prescriptions, a 21% quarter-over-quarter increase, indicating the company's increasing market penetration in the gastrointestinal sector and further solidifying its market position.
- Optimistic Future Outlook: Management anticipates achieving operational profitability in 2026 and cash flow positivity by 2027, emphasizing the successful execution of its GI strategy and the effectiveness of its sales team, laying a solid foundation for continued growth in the future.
See More
Phathom Pharmaceuticals Set to Announce Q4 Earnings
- Earnings Announcement Date: Phathom Pharmaceuticals is set to release its Q4 2023 earnings on February 26 before market open, with a consensus EPS estimate of -$0.19, reflecting a significant year-over-year improvement of 75.9%, indicating potential recovery in profitability.
- Revenue Growth Expectations: The anticipated revenue for Q4 is $57.44 million, representing a robust year-over-year increase of 93.4%, which underscores Phathom's strong market demand and sales performance, potentially enhancing its attractiveness for future investments.
- Performance Beat Record: Over the past year, Phathom has beaten EPS estimates 50% of the time and revenue estimates 75% of the time, demonstrating the company's reliability in financial forecasting and adaptability to market conditions.
- Estimate Revision Dynamics: In the last three months, EPS estimates have seen 2 upward revisions and 1 downward revision, while revenue estimates have experienced 6 upward revisions with no downward adjustments, indicating growing analyst confidence in Phathom's future performance.
See More
Barclays Upgrades Phathom to Overweight Amid Sales Recovery Prospects
- Rating Upgrade: Barclays upgraded Phathom Pharmaceuticals (PHAT) from equal weight to overweight, reflecting confidence in the anticipated sales recovery of its heartburn drug Voquezna, with significant growth expected in Q2.
- Price Target Adjustment: The bank raised its price target for Phathom from $16 to $18, indicating approximately 67% upside based on the March 26 close, showcasing a positive outlook on the company's future performance.
- Improving Sales Trends: Despite a ~36% year-to-date decline in Phathom's stock price, analysts noted positive sales trends in March, particularly with prescriptions peaking on March 13, surpassing levels seen in Q4 2025, indicating a rebound in market demand.
- Strategic Commercial Focus: Phathom's targeted approach towards gastrointestinal providers rather than a broader GI and primary care focus may serve as a tailwind for increased adoption of Voquezna, suggesting that this strategic positioning could enhance market penetration.
See More
PHATHOM PHARMACEUTICALS INC.: BARCLAYS INCREASES TARGET PRICE FROM $16 TO $18
- Analyst Update: Barclays has raised the price target for Phathom Pharmaceuticals from $16 to $18.
- Market Implications: This adjustment reflects a positive outlook on the company's performance and potential growth in the pharmaceutical sector.
See More
Surge in Options Trading Volume for Adobe and Phathom Pharmaceuticals
- Adobe Options Volume: Adobe Inc saw options trading volume of 58,412 contracts, equivalent to approximately 5.8 million shares, representing about 88.3% of its average daily trading volume of 6.6 million shares over the past month, indicating strong market interest in its future performance.
- High Put Option Activity: Notably, the $290 strike put option has seen 5,001 contracts traded today, representing around 500,100 shares of Adobe, reflecting investor expectations for potential price declines.
- Phathom Options Activity: Phathom Pharmaceuticals Inc recorded an options trading volume of 10,012 contracts, equivalent to approximately 1.0 million shares, which is about 86.9% of its average daily trading volume of 1.2 million shares over the past month, showcasing significant market interest.
- Call Option Trading: For Phathom, the $7.50 strike call option has also seen a trading volume of 5,001 contracts today, representing approximately 500,100 shares, indicating investor confidence in the company's future price appreciation.
See More
Emerging Trends in H. pylori Infection Market
- Market Size Growth: The H. pylori infection market is projected to reach $270 million by 2025, with the U.S. accounting for 85% of this market, indicating strong demand for new therapies and significant future market potential.
- Emerging Therapy Development: New therapies like Rifasutenizol from TenNor Therapeutics show over 90% eradication rates in clinical trials, potentially becoming the first innovative therapy for H. pylori, enhancing treatment efficacy and reducing resistance risks.
- Optimized Treatment Strategies: The incorporation of bismuth into triple therapy has increased eradication rates by 30-40%, reflecting effective strategies against antibiotic-resistant H. pylori and driving improvements in treatment standards.
- Adult-Pediatric Treatment Differences: Adult guidelines emphasize widespread eradication to lower gastric cancer risks, while pediatric recommendations require more cautious, targeted strategies, creating opportunities for personalized prevention and intervention programs.
See More
Phathom Pharmaceuticals Q4 2025 Earnings Call Highlights
- Strong Financial Performance: Phathom Pharmaceuticals reported Q4 2025 net revenues of $57.6 million, reflecting a 16% sequential growth, indicating significant improvements in sales and operational efficiency, with 2026 revenue guidance projected between $320 million and $345 million, showcasing robust market demand and growth potential.
- Capital Structure Optimization: The company successfully completed a $130 million equity offering and renegotiated debt terms, reducing the loan interest rate from 12% to 9.85%, which will significantly alleviate future financial burdens and enhance the company's financial flexibility and sustainability.
- Significant Prescription Growth: To date, total prescriptions for VOQUEZNA have exceeded 1.1 million, with Q4 alone reaching 273,000 prescriptions, a 21% quarter-over-quarter increase, indicating the company's increasing market penetration in the gastrointestinal sector and further solidifying its market position.
- Optimistic Future Outlook: Management anticipates achieving operational profitability in 2026 and cash flow positivity by 2027, emphasizing the successful execution of its GI strategy and the effectiveness of its sales team, laying a solid foundation for continued growth in the future.
See More
Phathom Pharmaceuticals Set to Announce Q4 Earnings
- Earnings Announcement Date: Phathom Pharmaceuticals is set to release its Q4 2023 earnings on February 26 before market open, with a consensus EPS estimate of -$0.19, reflecting a significant year-over-year improvement of 75.9%, indicating potential recovery in profitability.
- Revenue Growth Expectations: The anticipated revenue for Q4 is $57.44 million, representing a robust year-over-year increase of 93.4%, which underscores Phathom's strong market demand and sales performance, potentially enhancing its attractiveness for future investments.
- Performance Beat Record: Over the past year, Phathom has beaten EPS estimates 50% of the time and revenue estimates 75% of the time, demonstrating the company's reliability in financial forecasting and adaptability to market conditions.
- Estimate Revision Dynamics: In the last three months, EPS estimates have seen 2 upward revisions and 1 downward revision, while revenue estimates have experienced 6 upward revisions with no downward adjustments, indicating growing analyst confidence in Phathom's future performance.
See More
